{"id":2417665,"date":"2021-10-29T07:48:28","date_gmt":"2021-10-29T11:48:28","guid":{"rendered":"https:\/\/www.valuewalk.com\/?p=2417665"},"modified":"2023-05-18T18:07:42","modified_gmt":"2023-05-18T22:07:42","slug":"how-dreameds-recent-ai-innovation-is-revolutionising-diabetes-care","status":"publish","type":"post","link":"https:\/\/www.valuewalk.com\/how-dreameds-recent-ai-innovation-is-revolutionising-diabetes-care\/","title":{"rendered":"How DreaMed\u2019s Recent AI Innovation Is Revolutionising Diabetes Care"},"content":{"rendered":"<p><i><span style=\"font-weight: 400\">Top US children\u2019s hospital is utilising DreaMed\u2019s FDA-approved AI platform to provide millions with access to sequestered diabetes staff and endocrinologists<\/span><\/i><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">An Israeli biotech startup, DreaMed, has developed an AI system that has the potential to completely renovate the way in which the healthcare industry approaches the treatment of diabetes.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Under the current system, the ratio of endocrinologists to cases is 1:41,000; as a consequence, over half of recorded diabetic cases result in medical mismanagement.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Since over 460 million people are affected by diabetes globally, according to the WHO, DreaMed\u2019s solution presents significant benefits.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Successful implementation would reduce administration costs associated with fewer clinical visits, an effort that could <\/span><a href=\"https:\/\/www.statista.com\/statistics\/281090\/estimated-healthcare-expenditures-to-treat-diabetes-in-us-and-china\/\" target=\"_blank\"><span style=\"font-weight: 400\">save the US billions<\/span><\/a><span style=\"font-weight: 400\"> of dollars per year.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">With the development of its artificial intelligence-utilising system, Advisor Pro, <\/span><a href=\"https:\/\/www.ibtimes.com\/new-agreement-places-dreamed-diabetess-innovative-ai-platform-leading-us-childrens-3322536\" rel=\"nofollow\" target=\"_blank\"><span style=\"font-weight: 400\">DreaMed<\/span><\/a><span style=\"font-weight: 400\"> has situated itself at the precipice of the healthcare industry\u2019s revolution in attempting to rectify the holistic and systemic mismanagement of diabetes cases that is occuring on a massive scale in the US\u2019s healthcare system.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Advisor Pro\u2019s focus has been guided towards helping those seek treatment for the ailment of Type 1 diabetes since 2018, when it was initially approved by the US Food and Drug Administration. Its expertise is based on over a decade of clinical research and data from hundreds of people suffering from diabetes, setting it apart from any other vendor in the diabetic digital healthcare industry.<\/span><\/p>\n<h3><span style=\"font-weight: 400\">A New, Groundbreaking Approach<\/span><\/h3>\n<p><span style=\"font-weight: 400\">Since its first authorisation by the FDA, Advisor Pro\u2019s recent progressions have driven it to new heights; namely, the unique medical equipment\u2019s capabilities were extended to include individuals suffering from type 2 diabetes now as well due to discoveries by the scientific team of DreaMed.<\/span><\/p>\n<p><span style=\"font-weight: 400\">All patients are different, so they are granted an exclusive profile in order to monitor their unique diabetic status and insulin levels. In order to manage the treatment of such highly variable conditions optimally, an acutely tailored and customised treatment plan, along with extensive supervision would normally be required.<\/span><\/p>\n<p><span style=\"font-weight: 400\">However, as a result of DreaMed\u2019s innovative product, each patient\u2019s data from their CGM, SMBG and insulin pump is stored in their platform; this data is then used by an AI system designed by leading clinicians and endocrinologists to generate a treatment plan that is just as helpful to the patient, yet infinitely simpler in its process.<\/span><\/p>\n<p><span style=\"font-weight: 400\">A simpler, more efficient process requires less clinical visits, which reduces the administrative costs associated with treatment (equating to billions of dollars a year alone). Therefore, DreaMed presents an opportunity to such healthcare providers, as well as the industry as a whole, the chance at a substantial financial advantage.<\/span><\/p>\n<h3><span style=\"font-weight: 400\">Why This Is Special<\/span><\/h3>\n<p><span style=\"font-weight: 400\">The benefits of DreaMed\u2019s product are not limited to the financial realm, and actually include tangible benefits for the receivers of treatment as well. Moreover, leading pediatricians have gone on record to state that the Advisor Pro has been improving patient quality of life since the clinical trials phase.<\/span><\/p>\n<p><span style=\"font-weight: 400\">On top of this, the treatment will be significantly less financially intrusive for the patient as a result of the reduced clinical appointments that will be required when the most efficient treatment plan is assigned from the start through the use of DreaMed\u2019s MD Logic-based algorithm. The plan that it develops eloquently and seamlessly elucidates the monitoring process of treatment, from the perspective of both the patient and the healthcare provider.<\/span><\/p>\n<p><span style=\"font-weight: 400\">This breakthrough is so incredibly important because its applicability is so widespread. Furthermore, it will connect millions of patients suffering from diabetes with lifesaving treatment that they might not otherwise have been under the old system. Given the scale of diabetes\u2019s impact (around 460 million currently, and nearly 700 million by 2045), this generational leap has been innovated at the perfect time to counter one of the World Health Organisation\u2019s most widespread, chronic diseases from around the world.<\/span><\/p>\n<h3><span style=\"font-weight: 400\">Closing Remarks<\/span><\/h3>\n<p><span style=\"font-weight: 400\">On balance, the breakthroughs that DreaMed have made with its innovative Advisor Pro system undoubtedly present a meaningful solution to one of the most inefficient treatments of a massively widespread disease. In doing so, it provides a better quality of life for the patients, alongside financial benefits for both patients and providers as a result of a more efficient treatment plan and the reduced number of clinical appointments this entails.<\/span><\/p>\n<p><span style=\"font-weight: 400\">It is no surprise that this company has developed such significant professional validation for the use of its AI algorithms to treat a plethora of chronic diseases. Clinical centres with a global reputation are so positively outspoken about this product, including Medtronic Diabetes, Yale-New Haven, Glooko and DexCom.<\/span><\/p>\n<p><span style=\"font-weight: 400\">With all that being said, there are still more improvements to be made. Whilst FDA approval and the consequential partnerships this have caused enable DreaMed to potentially benefit thousands of lives, their system is still faced with a myriad of obstacles if it hopes to offer advice that is comparable to the comprehensiveness and all overarching opinions of a human endocrinologist.<\/span><\/p>\n ","protected":false},"excerpt":{"rendered":"<p>Top US children\u2019s hospital is utilising DreaMed\u2019s FDA-approved AI platform to provide millions with access to sequestered diabetes staff and &#8230; <a title=\"How DreaMed\u2019s Recent AI Innovation Is Revolutionising Diabetes Care\" class=\"read-more\" href=\"https:\/\/www.valuewalk.com\/how-dreameds-recent-ai-innovation-is-revolutionising-diabetes-care\/\" aria-label=\"More on How DreaMed\u2019s Recent AI Innovation Is Revolutionising Diabetes Care\">Read more<\/a><\/p>\n","protected":false},"author":21787,"featured_media":2417668,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[6641,104556],"tags":[],"states":[],"acf":[],"modified_by":"Umair Tariq","_links":{"self":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2417665"}],"collection":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/users\/21787"}],"replies":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/comments?post=2417665"}],"version-history":[{"count":1,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2417665\/revisions"}],"predecessor-version":[{"id":2465510,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2417665\/revisions\/2465510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media\/2417668"}],"wp:attachment":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media?parent=2417665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/categories?post=2417665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/tags?post=2417665"},{"taxonomy":"states","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/states?post=2417665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}